Ipsen's Iqirvo Competes with Gilead's Livdelzi in PBC Market
![Ipsen's Iqirvo Competes with Gilead's Livdelzi in PBC Market](https://investorshangout.com/images/blog/ihnews-Ipsen%27s%20Iqirvo%20Competes%20with%20Gilead%27s%20Livdelzi%20in%20PBC%20Market.jpg)
Introduction to Iqirvo and Livdelzi in Primary Biliary Cholangitis
The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of Ipsen’s Iqirvo (elafibranor) followed by Gilead’s Livdelzi (seladelpar). Both treatments are oral peroxisome proliferator-activated receptor (PPAR) therapies, representing significant advancements in PBC treatment in nearly a decade. These new assets were approved for use in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA.
Market Perception and Physician Preferences
One month prior to Iqirvo’s approval, Spherix Global Insights surveyed gastroenterologists and liver specialists to gauge their perceptions on the PBC pipeline. Participating specialists showed a clear preference for Livdelzi over Iqirvo, with nearly half selecting the Gilead brand as their preferred PBC treatment in development. This contrast was in favor of Ipsen’s asset, which garnered support from less than a third of those surveyed. The preference for Livdelzi was attributed to its efficacy data and effectiveness in treating pruritus, a chronic itch common among PBC patients. As one physician indicated, "Livdelzi seems to meet its primary endpoint the highest out of all drugs with the least adverse events and shows some improvement in helping with itching (pruritus)."
Launch Dynamix™ Service Insights
As part of the Launch Dynamix™ service, Spherix will closely track the uptake of both Iqirvo and Livdelzi over the first eighteen months of their availability. Initial tracking for Iqirvo showed that approximately three-quarters of participating specialists were aware of its approval, with the brand recognized as a significant advancement over existing PBC treatment options. Moreover, just one month post-launch, half of the respondents indicated a current or anticipated trial of Iqirvo within the next three months.
Competitive Landscape and Future Monitoring
While Iqirvo has shown strong successful launch indicators early on, the evolving competitive landscape with the introduction of Livdelzi will likely influence future perceptions and adoption. Spherix will continue to monitor both product launches, assessing the competitive dynamics and their implications for overall treatment strategies. The Launch Dynamix™ service is set to provide comprehensive evaluations of these factors.
About Spherix Global Insights
Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspectives of the extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. Those interested in learning more about Spherix Global Insights can visit their website or connect through LinkedIn for further information on their research and services.
Frequently Asked Questions
What is Iqirvo and what condition does it treat?
Iqirvo, also known as elafibranor, is a treatment approved for patients suffering from primary biliary cholangitis (PBC) and is used in conjunction with ursodeoxycholic acid (UDCA) or as monotherapy.
How does Livdelzi compare to Iqirvo in terms of physician preference?
Recent surveys indicated that many physicians favored Livdelzi over Iqirvo, citing its efficacy data and reduced adverse event profiles as key reasons for preference.
What is the Launch Dynamix™ service by Spherix?
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products, tracking their uptake and evaluating competitive dynamics for up to 18 months post-launch.
How are both Iqirvo and Livdelzi expected to perform in the market?
While Iqirvo has had a strong launch, the competitive entry of Livdelzi could influence future market dynamics and the adoption rate of these treatments among specialists.
How does Spherix Global Insights support the life sciences industry?
Spherix provides comprehensive market intelligence and advisory services that help life sciences companies make informed decisions and leverage growth opportunities in the evolving specialty markets.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Curt Calaway Appointed CFO at Tyson Foods, Inc.
- Stran & Company Responds to Nasdaq Notification on Filing Delay
- NVIDIA Schedules Event for Financial Community Engagement
- Ulta Beauty Faces Challenges Amid Market Competition
- ARCA Biopharma Completes Merger with Oruka Therapeutics
- Dollar General's Stock Declines Amid Outlook Cut
- Current Water Technologies Reports Q2 2024 Financial Results
- Constellation Brands Announces Q2 Fiscal 2025 Financial Results
- Great Lakes Dredge & Dock Corporation Upgraded to B- Rating
- Market Update: Dow Rises Despite Nvidia Earnings Impact
- BIGG Digital Assets Inc. Announces Strong Q2 2024 Results
- StateHouse Reports Significant Growth in Q2 2024 Financials
- Pan American Energy Completes Phase 2 Earn-In for Big Mack
- Ultragenyx Announces Participation in Key Investor Conferences
- Intuitive Machines Secures $116.9M NASA Lunar Contract
- Innovative Ketamine-Based Treatment Collaboration
- Clearmind Medicine's Patent Application for Ketamine Innovations
- Global Hand Gesture Sensor Market Growth and Trends
- Aircraft Seat Actuation System Market Growth Insights
- International Money Express Secures $425 Million Credit Facility
- Kane Biotech Reports Strong Q2 2024 Financial Performance
- Enviri Corporation Sells Reed Minerals for $45 Million
- IBEX Limited Announces FY2024 Financial Results Details
- GoHealth at H.C. Wainwright Annual Investment Conference
- Rail Vision Releases Strong Financial Results for H1 2024
Recent Articles
- Planet Green Welcomes Dr. Raymond Goldie to Advisory Board
- Meritage Homes Unveils 2023 Environmental and Governance Report
- Kane Biotech Reports Strong Q2 2024 Financial Performance
- Nvidia's Earnings Report: Adjustments and Future Prospects
- Wealth Competition: Bettencourt Meyers vs. Walton
- Havila Kystruten AS Reports Strong Q2 2024 Results
- Credit Agricole Capital Increase for Employees
- AnaptysBio to Attend Key Investor Conferences in September
- Walgreens Boots Alliance at Risk of Dividend Cuts
- Sono Motors Partners with Hofmeister & Meincke on Solar Bus Kit
- iRhythm Technologies Launches Zio Cardiac Monitoring in Europe
- iRhythm Technologies Launches Zio® Monitoring Service Across Europe
- Alignment Health Plan Achieves High Customer Satisfaction Rating
- Nuvectis Pharma's NXP800 Receives FDA Orphan Drug Designation
- Zevra Therapeutics Announces Investor Conference Participation
- KANZHUN LIMITED Unveils New Share Repurchase Initiative
- Investing Insights: Stock Splits and Growth Potential
- Evaluating Rivian and Archer: Growth Potential and Risks
- Global Healthcare Cleanroom Consumables Market Growth
- InterDigital Presents Advanced Video Solutions at IBC 2024
- Ontex Launches Innovative Dreamshield 360º Baby Pants Technology
- Global Barcode Verifiers Market Growth Forecast 2033
- Silvano Fashion Group Reports Q2 and 6M 2024 Financial Performance
- HP Inc. Focuses on Cost Cuts and AI PCs for Growth
- Significant Decline for Super Micro Computer Stock